Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2020

View Archived Issues

Oncometabolites mask DNA repair signals

Tychan initiates phase I trials with TY-027 for COVID-19

Estrogen precursor drives breast cancer in obese postmenopausal women

First patient with ovarian cancer dosed in second phase I study of Radspherin

Namilumab and infliximab announced as first drugs to be evaluated in major COVID-19 trial

Phase II study of Leukine in recipients of haploidentical cell transplant

Qualigen and UofL to develop AS-1411 for the treatment of COVID-19

Ausio Pharmaceuticals presents early clinical data for S-equol in TNBC

ANGPT2 as novel diagnostic biomarker for primary lymphedema

USP48 found to be involved in hereditary hearing loss in animal model

Nflection Therapeutics divulges new MAP2K1 inhibitors

Hinova Pharmaceuticals presents EP300 inhibitors

New HBV antivirals identified by Enanta Pharmaceuticals

Xios Therapeutics synthesizes new adenosine A2A and A2B receptor antagonists

IFM Due discovers new hSTING antagonists

Medicenna Therapeutics' IL-2 superkine MDNA-11 inhibits tumor growth

Otsuka reports topline phase III results for centanafadine in adults with ADHD

FDA approves Uplizna to treat neuromyelitis optica spectrum disorder

CytoDyn initiates phase II study of leronlimab for NASH

Survival benefit seen with RC-48-ADC in gastric or gastro-esophageal junction cancer patients

PACS1 gene variants cause a form of epileptic encephalopathy

Optimization of a spiroindolinone-based tankyrase inhibitor blocking WNT pathway in colon cancer

Cathelicidin gene is downregulated in the brain of depressed individuals who died by suicide

PiCoVacc, an inactivated vaccine candidate for SARS-CoV-2, offers complete protection in macaques

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...